Premium
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors
Author(s) -
Jimeno Antonio,
Daw Najat C.,
Amador Maria L.,
Cusatis George,
Kulesza Peter,
Krailo Mark,
Ingle Ashish M.,
Blaney Susan M.,
Adamson Peter,
Hidalgo Manuel
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20753
Subject(s) - gefitinib , medicine , epidermal growth factor receptor , oncology , blood cancer , vascular endothelial growth factor , vegf receptors , cancer
Abstract This trial evaluated the effect of gefitinib on the plasma circulating levels of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP)‐2 and ‐9 of patients treated on a pediatric Phase I trial. Complete plasma correlative studies were obtained from 16 of the 25 enrolled patients. There was a trend for lower MMP‐2 baseline levels in patients with partial response or stable disease. The Ewing sarcoma from the only patient with partial response lacked egfr mutations. Gefitinib did not induce any significant variation in the levels of the assessed parameters, and none of these determinations showed significant predictive or prognostic value. Pediatr Blood Cancer 2007;49:352–357. © 2006 Wiley‐Liss, Inc.